Streetwise Reports Examines How Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential
SAN FRANCISCO, CA--(Marketwired - September 21, 2017) - André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe. Included in this article is: ProMIS …